Estimation of Oral Bioavailability of a Long Half-Life Drug in Healthy Subjects

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Pharmaceutical Research

• Publication date

  1998-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1023/A:1011977116543PMID 9834003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety.

  1996cited by this paper
• Drug and alternative therapies for hyperlipidemia.

  1994cited by this paper
• Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.

  1993cited by this paper
• Isopentenoid synthesis in isolated embryonic Drosophila cells. Farnesol catabolism and omega-oxidation.

  1988cited by this paper

• The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis

  2023cites this paper
• Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against Staphylococcus aureus

  2017cites this paper
• Title : Beyond conventional antibiotics for the future treatment of methicillin-3 resistant Staphylococcus aureus infections : Two novel alternatives . 4 5 6

  2015cites this paper
• Non‐Compartmental Analysis

  2014cites this paper
• Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid

  2014cites this paper
• Evaluation of the Collective Impact of Passive Permeability and Active Transport on In Vivo Blood‐Brain Barrier and Gastrointestinal Drug Absorption

  2014cites this paper
• Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

  2013cites this paper
• Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives.

  2012cites this paper
• Assessing product bioequivalence for extended-release formulations and drugs with long half-lives.

  2012cites this paper
• Glycoconjugates: A Brief Overview

  2011cites this paper
• Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents.

  2011cites this paper
• Emerging targets for the treatment of dyslipidemia.

  2011cites this paper
• Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus.

  2009cites this paper
• EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.

  2009cites this paper
• Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.

  2008cites this paper
• A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence

  2008cites this paper
• Genetics and molecular biology: a cholesterol-lowering drug with antibacterial properties.

  2008cites this paper
• Manipulation of isoprenoid biosynthesis in mevalonate kinase deficiency

  2008cites this paper
• Novel molecules targeting dyslipidemia and atherosclerosis.

  2008cites this paper
• “Superbugs Bunny” Outsmarts Our Immune Defense

  2008cites this paper
• Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency.

  2006cites this paper
• Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.

  2006cites this paper
• Prediction of the Oral Absorption of Low-Permeability Drugs Using Small Intestine-Like 2/4/A1 Cell Monolayers

  2003cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of a New Squalene Synthase Inhibitor, BMS‐188494, in Healthy Volunteers

  1998cites this paper